License And Supply Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Reata Pharmaceuticals Inc – FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Milestone Payments, Supply Price and Products Manufacturing (December 7th, 2017)

This Fourth Supplement (herein so called), effective as of December 6, 2017 (the "Supplement Effective Date"), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the "Original Agreement"), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 ("Reata"), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan ("Kyowa Kirin"). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a "Party" and collectively as the "Parties".

Reata Pharmaceuticals Inc – THIRD SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (Alport Syndrome) in Japan (December 7th, 2017)

This Third Supplement (herein so called), effective as of December 6, 2017 (the "Supplement Effective Date"), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the "Original Agreement"), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 ("Reata"), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan ("Kyowa Kirin"). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a "Party" and collectively as the "Parties".

BeiGene, Ltd. – License and Supply Agreement (November 13th, 2017)

This Agreement dated as of July 5, 2017 (the "Execution Date") and effective on the Effective Date (as defined below), is entered into between Celgene Logistics Sarl, a corporation incorporated under the laws of Switzerland, with registered offices at Route de Perreux 1, 2017 Boudry Switzerland ("Celgene"), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having an address of c/o Mourant Ozannes Corporate Services, (Cayman) Limited 94 Solaris Avenue, PO Box 1348, Grand Cayman KY1-1108, Cayman Islands GB ("BeiGene").

[RUSSIAN TRANSLATION] ADDITIONAL AGREEMENT No. 3 to the Development, License and Supply Agreement Dated August 1st, 2013 (November 7th, 2017)

Joint Stock Company R-Pharm, represented by its General Director Ignatiev V.G., acting on the basis of the Chapter, hereinafter referred to as the "R-Pharm" on the one hand, and

[RUSSIAN TRANSLATION] AMENDMENT to the Development, License and Supply Agreement Dated 01 August 2013 (November 7th, 2017)

R-PHARM JSC, a joint stock company incorporated and existing under the laws of the Russian Federation and having its principal office at Berzarina street, 19, bld. 1, Moscow, 123154, Russia, Principal State Registration Number (OGRN) 1027739700020 ("R-Pharm") and

[RUSSIAN TRANSLATION] ADDITIONAL AGREEMENT No. 2 to the Development, License and Supply Agreement Dated August 1st, 2013 (November 7th, 2017)

Joint Stock Company R-Pharm, represented by its General Director lgnatiev V .G., acting on the basis of the Chapter, hereinafter referred to as the "R-Pharm" on the one hand, and

Exclusive License and Supply Agreement (August 9th, 2017)

THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (this "Agreement") is made and entered into as of May 12, 2015 (the "Effective Date"), by and between Faes Farma, S.A., a corporation (sociedad anonima) organized under the Laws of Spain and having offices located at Avenida Autonomia 10, 48.940 Leioa (Biscay) Spain ("Faes"), and Marathon Pharmaceuticals, LLC, a limited liability company organized under the Laws of the State of Delaware (U.S.A.) and having offices located at 1033 Skokie Boulevard, Suite 600, Northbrook, Illinois 60062 U.S.A. ("Marathon"). Faes and Marathon are sometimes individually referred to herein as a "Party" and collectively as the "Parties".

Reata Pharmaceuticals Inc – Second Supplement to Exclusive License and Supply Agreement (June 23rd, 2017)

This Second Supplement (herein so called), effective as of March 21, 2017 (the Supplement Effective Date), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the Original Agreement), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (Reata), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-9-2 Ohtemachi, Chiyoda-ku, Tokyo, 100-0004, Japan (Kyowa Kirin). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Nephros, Inc. – Third Amendment to License and Supply Agreement (May 9th, 2017)

This THIRD AMENDMENT TO LICENSE AND SUPPLY AGREEMENT (this "Amendment") is entered into as of May 5th, 2017, by and between Nephros, Inc., a Delaware corporation ("Nephros"), and Medica S.p.A. ("Medica"), and sometimes referred to individually as a "Party" and collectively as the "Parties".

Columbia Laboratories, Inc. – AMENDMENT No. 2 TO THE AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT (March 7th, 2017)

This Amendment to the Amended and Restated License and Supply Agreement is made and entered into as of this 12th day of December, 2016, by and between Columbia Laboratories (Bermuda) Limited, a Bermuda corporation having its principal place of business at Canon's Court, 22 Victoria Street, PO Box HM 1179, Hamilton HM 12, Bermuda ("Licensor"), and Ares Trading S.A., a Swiss company with its principal place of business at c/o Zone Industrielle, 1267 Coinsins, Switzerland ("Licensee").

Amendment One to the Third Amendment to Trademark License and Supply Agreement (November 4th, 2016)

This Amendment One dated September 12, 2016 (the "Effective Date") to the Third Amendment dated March 17, 2016 (the "Amendment") to the Trademark License and Supply Agreement ("Agreement") dated May 28, 2014 ("Effective Date") as amended July 28, 2014 and September 30, 2015 by and between Mission Pharmacal Company ("Mission") and Retrophin, Inc. (together with its affiliates, "Retrophin").

Versartis, Inc. – Exclusive License and Supply Agreement (November 4th, 2016)

This Exclusive License and Supply Agreement (this "Agreement") effective as of August 5, 2016 (the "Effective Date"), is by and between Versartis GmbH, a corporation organized and existing under the laws of Switzerland, with an address at Muhlenberg 7, 4052 Basel, Switzerland ("GmbH"), and Versartis, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 4200 Bohannon Drive #250, Menlo Park, CA 94025, on behalf of itself and its Affiliates (collectively, "Versartis US"), (Versartis US and GmbH referred to herein collectively as "Versartis"), on the one hand, and Teijin Limited, a company organized and existing under the laws of Japan, with an address at 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-8585, Japan ("Teijin"), on the other hand. Versartis and Teijin may be referred to herein each as a "Party" and collectively as the "Parties".

American Home Alliance Corp – FIRST AMENDMENT TO DISTRIBUTION, LICENSE AND SUPPLY AGREEMENTentered Into as of the 22ndday of June, 2016 (The "First Amendment") BETWEEN: KNIGHT THERAPEUTICS INC., a Corporation (July 14th, 2016)

WHEREAS Ember and Knight are parties of a certain Distribution, License and Supply Agreement (the "Distribution Agreement"), made as of the 3rd day of August, 2015.

Alexza Pharmaceuticals – Amendment No. 2 to License and Supply Agreement (Restructuring) (May 13th, 2016)

This Amendment No. 2 to License and Supply Agreement (this "Second Amendment") is executed on and effective as of February 23, 2016 (the "Second Amendment Effective Date"), by and between Alexza Pharmaceuticals, Inc., a company organized under the laws of the State of Delaware, United States ("Alexza"), and having a principal place of business at 2091 Stierlin Court, Mountain View, CA 94043, United States, and Teva Pharmaceuticals USA, Inc., a company organized under the laws of Delaware, United States ("Teva"), having a principal place of business at 1090 Horsham Road, North Wales, PA 19454, United States.

Second Amendment to Trademark License and Supply Agreement (May 5th, 2016)

A Trademark License and Supply Agreement (the "Agreement") was entered into by and between MISSION PHARMACAL COMPANY ("Mission") and RETROPHIN, INC. ("Retrophin") on May 28, 2014.

Third Amendment to Trademark License and Supply Agreement (May 5th, 2016)

This Third Amendment dated March 17, 2016 (the "Amendment") to the Trademark License and Supply Agreement ("Agreement") dated May 28, 2014 ("Effective Date") as amended July 28, 2014 and September 30, 2015 by and between Mission Pharmacal Company ("Mission") and Retrophin, Inc. (together with its affiliates, "Retrophin").

VaxGen – License and Supply Agreement (April 29th, 2016)

This License and Supply Agreement (the "Agreement") is made and entered into by and between diaDexus, Inc., located at 349 Oyster Point Boulevard, South San Francisco, CA 94080-1913 (hereinafter "Licensor"), and OriGene Technologies, Inc., located at 9620 Medical Center Dr., Suite 200, Rockville, MD 20850 ("OriGene"), and Wuxi OriGene Biotechnology Co., Ltd, a corporation organized under the laws of China located at No. 168, Meiliang RD, Mashan, Binhu District Wuxi City, Jiangsu Province, 214092 China, which is an Affiliate of OriGene ("WOBC") (OriGene and WOBC are referred to herein collectively as "Licensee"), effective as of September 4, 2015, (the "Effective Date"). Licensor, OriGene and WOBC may be referred to herein individually as a "Party", and collectively as the "Parties".

Aytu Bioscience, Inc – LICENSE AND SUPPLY AGREEMENT BETWEEN ACERUS PHARMACEUTICALS SRL and AYTU BIOSCIENCE, INC. Dated as of April 22, 2016 LICENSE AND SUPPLY AGREEMENT (April 25th, 2016)

This LICENSE AND SUPPLY AGREEMENT (this "Agreement") is made and effective as of April 22, 2016 (the "Effective Date") by and among Acerus Pharmaceuticals SRL, a society with restricted liability, having its principal office at Suite B, Durants Business Center, Durants, Christ Church, Barbados ("Acerus") and Aytu Bioscience, Inc., a Delaware corporation, having its principal office at 373 Inverness Parkway, Suite 206 Englewood, CO 80112 ("Aytu") (each of Acerus and Aytu being a "Party," and collectively, the "Parties").

Midatech Pharma Plc – CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS ([***]) DENOTE SUCH OMISSIONS. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THIS OMITTED INFORMATION. LICENSE AND SUPPLY AGREEMENT by and Between MONOSOL RX, LLC, and GALENA BIOPHARMA, INC. (April 14th, 2016)

This LICENSE AND SUPPLY AGREEMENT (together with any Schedules hereto, this "Agreement") is entered into as of July 17, 2014 by and between MonoSol Rx, LLC, a Delaware limited liability company ("MSRx"), and Galena Biopharma, Inc., a Delaware corporation ("Galena"). MSRx and Galena are sometimes referred to hereinafter individually as a "Party" and collectively as the "Parties."

Reata Pharmaceuticals Inc – SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (CTD-PAH) in Japan (March 22nd, 2016)

This Supplement (herein so called), effective as of, January 1, 2016 (the "Supplement Effective Date"), to the Exclusive License and Supply Agreement, effective as of December 24, 2009 (the "Original Agreement"), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 ("Reata"), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan ("Kyowa Kirin"). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a "Party" and collectively as the "Parties".

Cumberland Pharmaceuticals Inc. – LICENSE AND SUPPLY AGREEMENT by and Between GASTRO-ENTERO LOGIC, LLC, and CUMBERLAND PHARMACEUTICALS INC. Dated as of November 16, 2015 (March 14th, 2016)

This LICENSE AND SUPPLY AGREEMENT ("Agreement") is entered into this 16th day of November, 2015 ("Effective Date"), by and between Cumberland Pharmaceuticals Inc., a Tennessee corporation having a place of business at 2525 West End Avenue, Suite 950, Nashville, TN 37203 ("CPI") and Gastro-Entero Logic, LLC, a Delaware limited liability company, having a registered office located at 3500 South DuPont Highway, Dover, County of Kent, Delaware, 19901 ("GEL"). CPI and GEL are referred to herein collectively as the "Parties" and sometimes individually as a "Party".

Endo International plc – Amended and Restated License and Supply Agreement (February 29th, 2016)

THIS AMENDED AND RESTATED LICENSE AND SUPPLY AGREEMENT (this "Agreement"), dated as of December 11, 2015 (the "Execution Date") and effective as of July 1, 2016 (the "Effective Date"), by and among NOVARTIS, AG, a Swiss corporation having a principal place of business in Basel, Switzerland ("NOVARTIS AG"), SANDOZ INC., a Delaware corporation having a principal place of business at 100 College Rd. West, Princeton, NJ 08540 ("SANDOZ," and together with NOVARTIS AG, the "NOVARTIS Parties") and ENDO VENTURES LIMITED, an Irish private company limited by shares having a principal place of business at First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin 4, Ireland ("ENDO"). Each of the NOVARTIS Parties and ENDO is referred to herein individually as a "Party" and collectively as the "Parties."

American Home Alliance Corp – Distribution, License and Supply Agreement (February 3rd, 2016)

THIS AGREEMENT, effective August 3 2015, by and between EMBER THERAPEUTICS, INC., a company incorporated under the laws of State of Delaware ("Ember") and KNIGHT THERAPEUTICS INC., a public limited liability company incorporated under the laws of Canada ("Knight").

Reata Pharmaceuticals Inc – EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and Between REATA PHARMACEUTICALS, INC. And KYOWA HAKKO KIRIN CO. LTD. (January 4th, 2016)

This Exclusive License and Supply Agreement (this Agreement) effective as of December 24, 2009 (the Effective Date), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (Reata), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (Kyowa Kirin). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Portions of This Exhibit Have Been Omitted Pursuant to a Request for Confidential Treatment Pursuant to 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2(b). The Omitted Portions, Marked by [***], Have Been Separately Filed With the Securities and Exchange Commission. AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and Between PFIZER INC. And PROTALIX LTD. October 12, 2015 (December 11th, 2015)

This Amended and Restated Exclusive License and Supply Agreement (this "Agreement") dated as of October 12, 2015 (the "Second Amendment Effective Date") between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel ("Protalix"), and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. ("Pfizer").

Reata Pharmaceuticals Inc – EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and Between REATA PHARMACEUTICALS, INC. And KYOWA HAKKO KIRIN CO. LTD. (November 20th, 2015)

This Exclusive License and Supply Agreement (this Agreement) effective as of December 24, 2009 (the Effective Date), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (Reata), and Kyowa Hakko Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (Kyowa Kirin). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a Party and collectively as the Parties.

Endo International plc – Amendment No. 2 to License and Supply Agreement (November 9th, 2015)

This Amendment No. 2 to License and Supply Agreement (this "Amendment") is entered into with effect as of December 31, 2012 ("Amendment Effective Date"), by and among Endo Pharmaceuticals Inc., a Delaware corporation having a principal place of business at 100 Endo Drive, Chadds Ford, Pennsylvania 19317 ("Endo"), Novartis Consumer Health, Inc., a Delaware corporation having a principal place of business at 200 Kimball Drive, Parsippany, New Jersey 07054 ("Novartis"), and Novartis AG, a Swiss corporation having a principal place of business in Basel, Switzerland ("Novartis AG"). Each of Novartis AG, Novartis and Endo is referred to herein individually as a "Party" and collectively as the "Parties."

Endo International plc – Amendment No. 1 to License and Supply Agreement (November 9th, 2015)

This Amendment No. 1 to that certain License and Supply Agreement (this "Amendment") is entered into as of March 28, 2008, by and among Novartis AG, Novartis Consumer Health, Inc. (collectively, "Novartis") and Endo Pharmaceuticals Inc. ("Endo").

AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and Between PFIZER INC. And PROTALIX LTD. October 12, 2015 (November 9th, 2015)

This Amended and Restated Exclusive License and Supply Agreement (this "Agreement") dated as of October 12, 2015 (the "Second Amendment Effective Date") between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel ("Protalix"), and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. ("Pfizer").

Endo International plc – LICENSE AND SUPPLY AGREEMENT by and Among NOVARTIS, AG, NOVARTIS CONSUMER HEALTH, INC. And ENDO PHARMACEUTICALS INC. Dated as of March 4, 2008 (November 9th, 2015)

THIS LICENSE AND SUPPLY AGREEMENT (this "Agreement"), dated as of March 4, 2008 (the "Execution Date"), by and among NOVARTIS, AG, a Swiss corporation having a principal place of business in Basel, Switzerland ("NOVARTIS AG"), NOVARTIS CONSUMER HEALTH, INC., a Delaware corporation having a principal place of business at 200 Kimball Drive, Parsippany, New Jersey 07054 ("NOVARTIS," and collectively with NOVARTIS AG, the "NOVARTIS Parties") and ENDO PHARMACEUTICALS INC., a Delaware corporation having a principal place of business at 100 Endo Drive, Chadds Ford, Pennsylvania 19317 ("ENDO"). Each of NOVARTIS and ENDO is referred to herein individually as a "Party" and collectively as the "Parties."

Re: Addendum to Trademark License and Supply Agreement Dated May 28, 2014 Dear Stephen, (November 6th, 2015)

As you are aware, Retrophin has requested that Mission Pharmacal build a significant safety stock of tiopronin, the active pharmaceutical ingredient (API) in THIOLA. The safety stock is requested to insure that there is no interruption in the supply of THIOLA and to prepare for a potential development project, whereby THIOLA may be reformulated. Due to the financial burden of purchasing such large quantities of tiopronin prior to firm production orders, Mission is requesting immediate reimbursement for the safety stock purchases.

VaxGen – License and Supply Agreement (October 30th, 2015)

This License and Supply Agreement (the "Agreement") is made and entered into by and between diaDexus, Inc., located at 349 Oyster Point Boulevard, South San Francisco, CA 94080-1913 (hereinafter "Licensor"), and OriGene Technologies, Inc., located at 9620 Medical Center Dr., Suite 200, Rockville, MD 20850 ("OriGene"), and Wuxi OriGene Biotechnology Co., Ltd, a corporation organized under the laws of China located at No. 168, Meiliang RD, Mashan, Binhu District Wuxi City, Jiangsu Province, 214092 China, which is an Affiliate of OriGene ("WOBC") (OriGene and WOBC are referred to herein collectively as "Licensee"), effective as of September 4, 2015, (the "Effective Date"). Licensor, OriGene and WOBC may be referred to herein individually as a "Party", and collectively as the "Parties".

Recro Pharma, Inc. – Supplemental Agreement No. 2 to the Amended and Restated License and Supply Agreement (Generic Verapamil) (August 14th, 2015)

This Supplemental Agreement No. 2 to the Amended and Restated License and Supply Agreement (Generic Verapamil) (Supplemental Agreement No. 2) is made the 17th day of January 2014 (Supplemental Agreement No. 2 Effective Date).

SteadyMed Ltd. – Exclusive License and Supply Agreement by and Between Cardiome Pharma Corp. And Correvio International Sarl and SteadyMed Ltd. (August 13th, 2015)

This Exclusive License and Supply Agreement (this Agreement) is made as of 28th June 2015 (the Effective Date), by and between CARDIOME PHARMA CORP., a company duly incorporated under the laws of Canada, with its principal place of business at 1441 Creekside Drive, 6th Floor, Vancouver BC V6J 4S7 and Correvio International Sarl, a company duly incorporated and existing under the laws of Switzerland, with its principal place of business at Rue des Alpes 21, 1201 Geneva, Switzerland (hereinafter collectively referred to as Cardiome), and STEADYMED LTD., a company organized and existing under the laws of Israel with its principal place of business at 5 Oppenheimer Street, Rehovot 7670105, Israel (SteadyMed). Each of Cardiome and SteadyMed is referred to individually as a Party and collectively as the Parties.

Exclusive License and Supply Agreement (August 13th, 2015)

THIS EXCLUSIVE LICENSE AND SUPPLY AGREEMENT (hereinafter referred to as the "Agreement") is made on May 12, 2015 (the "Effective Date") by and between Suntava, Inc. (hereinafter referred to as "Suntava"), a corporation with principal offices at 3290 St. Croix Trail, PO 268, Afton, MN 55001 and ChromaDex, Inc., with principal office at 10005 Muirlands Blvd., Suite G, Irvine, CA 92618 (hereinafter referred to as "ChromaDex").